rethinkTHC Search
Menu
Evidence in context

Cannabis Health Risks

The research base for cannabis health risks includes 84 peer-reviewed studies spanning 2025–2026. Of these, 7 provide strong evidence, including 4 meta-analyses and 0 randomized controlled trials. Key

Published summary: 2026-03-07

Where the evidence converges

Meta-analysis of 13 studies found prenatal cannabis exposure significantly increased odds of small-for-gestational-age and low birth weight outcomes

Strong evidence · 1 studies

Based on 13 studies with varying definitions of cannabis exposure. Could not account for dose, frequency, route, or timing of use. Many included studies relied on self-reported cannabis use, which lik

Study of 289,000 surgical patients found cannabis use disorder increased post-surgical cardiovascular risk by 26%, with recreational use risky only for those with high baseline cardiac risk

Moderate evidence · 7 studies

Based on limited number of strong-evidence studies.

Where questions remain

NHANES analysis of 3,690 adults found marijuana/hashish use associated with 4

Moderate evidence · 15 studies

Cross-sectional NHANES design cannot establish causation. Self-reported drug use may be inaccurate. Cannabis smoke exposure patterns (frequency, duration, method) were not fully characterized. Residua

Connecticut crash-toxicology data linkage found alcohol, cannabis, and other drugs significantly predicted driver injury, with lack of safety equipment as the strongest predictor

Moderate evidence · 15 studies

The study covers a single state (Connecticut) and relies on toxicology data that may not reflect impairment at the time of the crash. The counterintuitive finding about driver errors suggests the mode

Large cohort study of 363,952 births found prenatal cannabis use associated with a rare abdominal wall defect (omphalocele) but not with 36 other major birth defects

Moderate evidence · 15 studies

Observational design cannot prove causation. Cannabis exposure was measured at prenatal care entry, not throughout pregnancy. Could not account for potency, frequency, or route of use. Very small numb

Removing cannabis as a urine drug screening indication in a maternity unit eliminated racial disparities in testing and CPS reporting without missing other substance use

Moderate evidence · 15 studies

Single center in one Midwestern city. Cannot fully separate the effect of removing cannabis indication from the clinical decision support component. Unmeasured confounders may exist.

Research gaps

  • Only 0 randomized controlled trials exist out of 84 studies — most evidence is observational or from reviews.
  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Key studies

Meta-Analysis Links Prenatal Cannabis to Smaller Babies

This meta-analysis pools evidence from multiple studies to provide a clearer picture of prenatal cannabis risks. The significant findings for birth size outcomes add confidence to what individual studies have suggested.

Meta-analysis found cannabis use associated with 53% higher all-cause mortality, but evidence quality was low

This is the first meta-analysis to synthesize evidence on cannabis use and all-cause mortality. The finding of a 53% increased risk is notable but comes with substantial caveats: high heterogeneity, potential confounding, and the association disappearing in patient populations suggest the relationsh

Cannabis Users Had 48% Higher Risk of Cardiovascular Events in Large Meta-Analysis

Whether cannabis causes cardiovascular disease has been debated for years. This meta-analysis of nearly 1.9 million people provides the strongest pooled estimate to date, showing a significant association with composite cardiovascular events even if individual endpoints fall short of significance.

Cannabis Use Linked to 29% Higher Heart Attack Risk and Double the Cardiovascular Death Risk

This is one of the most comprehensive quantitative assessments of cannabis cardiovascular risk. The elevated cardiovascular death risk (2.1x) is particularly concerning given increasing cannabis use and the often-overlooked cardiac effects.

CBD and THC Can Interfere With How Your Body Processes Other Medications

With millions of people using CBD products alongside prescription medications, understanding drug interactions is critical for safety. The strong inhibition of CYP3A4 alone is clinically significant — this enzyme metabolizes drugs like blood thinners, statins, and anti-seizure medications.

Cannabis use disorder increased post-surgical cardiovascular risk by 26% in a study of 289,000 patients

This is one of the largest studies linking cannabis use to post-surgical cardiovascular complications. The critical finding that risk depends on both the type of cannabis use (disorder vs recreational) and baseline cardiac risk provides actionable information for surgical risk assessment.

How the research developed

2020–present

84 studies published. Includes 4 meta-analyses, 7 strong-evidence studies.

How this summary was assembled

This consensus synthesizes 84 peer-reviewed studies: 4 meta-analyses (5%), 33 observational studies (39%), 9 reviews (11%), 9 case studies (11%), 29 other study types (35%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

These counts describe the source summary at publication. They may differ from the current library.